Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The physician's role in selecting a factor replacement therapy.

S W Pipe1

  • 1Pediatric Hemophilia and Coagulation Disorders Program, University of Michigan, Women's Hospital, Ann Arbor, 48109, USA. ummdswp@med.umich.edu

Haemophilia : the Official Journal of the World Federation of Hemophilia
|February 1, 2006
PubMed
Summary

The USA has eliminated blood-borne pathogen transmission in clotting therapies using screening and inactivation. Future threats from new pathogens require proactive strategies and patient-clinician dialogue for safe therapy choices.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioengineered molecules for the management of haemophilia: Promise and remaining challenges.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Advantage of recombinant von Willebrand factor for peri-operative management in paediatric acquired von Willebrand syndrome.

Haemophilia : the official journal of the World Federation of Hemophilia·2018
Same author

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies.

Haemophilia : the official journal of the World Federation of Hemophilia·2017
Same author

Minimal dataset for post-registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH.

Journal of thrombosis and haemostasis : JTH·2017
Same author

Evidence-based guidelines support integrated disease management as the optimal model of haemophilia care.

Haemophilia : the official journal of the World Federation of Hemophilia·2016

Area of Science:

  • Infectious disease transmission
  • Blood-borne pathogens
  • Therapeutic safety

Background:

  • Plasma-derived and recombinant therapies in the USA have achieved near-elimination of human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus transmissions over 20 years.
  • This success is attributed to robust screening and inactivation technologies for known infectious agents.
  • Emerging threats, such as non-lipid-enveloped viruses or prions, pose a risk due to potential ineffectiveness of current inactivation methods.

Purpose of the Study:

  • To review the success in eliminating known blood-borne pathogen transmissions in clotting therapies.
  • To identify potential future threats from emerging infectious diseases.
  • To recommend a proactive approach for managing risks associated with new pathogens in clotting therapies.

Related Experiment Videos

Main Methods:

  • Review of historical data on pathogen transmission in plasma-derived therapies.
  • Analysis of current screening and inactivation technologies.
  • Discussion of potential emerging pathogen risks and their implications.
  • Recommendations for clinical practice and patient engagement.

Main Results:

  • Significant reduction in HIV, HBV, and HCV transmission in US plasma-derived therapies over two decades.
  • Identification of non-lipid-enveloped viruses and prions as potential future threats.
  • Emphasis on the need for proactive strategies beyond current inactivation methods.

Conclusions:

  • Lessons learned from the HIV crisis can inform future responses to emerging infectious disease threats.
  • Clinicians must engage patients in informed decision-making regarding clotting factor therapies, considering various factors including pathogen risks.
  • Proactive risk management and open communication are essential for patient safety in the face of scientific uncertainty.